These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

206 related items for PubMed ID: 23122560

  • 1. M(2)-β(2) interaction: a basis for combined bronchodilator treatment.
    López-Campos JL.
    Arch Bronconeumol; 2013 Jul; 49(7):279-81. PubMed ID: 23122560
    [No Abstract] [Full Text] [Related]

  • 2. Multivalent dual pharmacology muscarinic antagonist and β₂ agonist (MABA) molecules for the treatment of COPD.
    Hughes AD, McNamara A, Steinfeld T.
    Prog Med Chem; 2012 Jul; 51():71-95. PubMed ID: 22520472
    [No Abstract] [Full Text] [Related]

  • 3. Triple inhalers for obstructive airways disease: will they be useful?
    Barnes PJ.
    Expert Rev Respir Med; 2011 Jun; 5(3):297-300. PubMed ID: 21702649
    [No Abstract] [Full Text] [Related]

  • 4. Seebri Neohaler and Utibron Neohaler for COPD.
    Med Lett Drugs Ther; 2016 Mar 28; 58(1491):39-41. PubMed ID: 27027687
    [No Abstract] [Full Text] [Related]

  • 5. [Role of bronchodilators in therapy for COPD-mechanisms of LABA and LAMA on airway smooth muscle].
    Kume H.
    Nihon Rinsho; 2016 May 28; 74(5):813-9. PubMed ID: 27254952
    [Abstract] [Full Text] [Related]

  • 6. Additive efficacy of short-acting bronchodilators on dynamic hyperinflation and exercise tolerance in stable COPD patients treated with long-acting bronchodilators.
    Kitaguchi Y, Fujimoto K, Komatsu Y, Hanaoka M, Honda T, Kubo K.
    Respir Med; 2013 Mar 28; 107(3):394-400. PubMed ID: 23245993
    [Abstract] [Full Text] [Related]

  • 7. The Influence of receptor kinetics on the onset and duration of action and the therapeutic index of NVA237 and tiotropium.
    Sykes DA, Dowling MR, Leighton-Davies J, Kent TC, Fawcett L, Renard E, Trifilieff A, Charlton SJ.
    J Pharmacol Exp Ther; 2012 Nov 28; 343(2):520-8. PubMed ID: 22854200
    [Abstract] [Full Text] [Related]

  • 8. Discovery of a novel class of inhaled dual pharmacology muscarinic antagonist and β2 agonist (MABA) for the treatment of chronic obstructive pulmonary disease (COPD).
    Rancati F, Linney ID, Rizzi A, Delcanale M, Knight CK, Schmidt W, Pastore F, Riccardi B, Mileo V, Carnini C, Cesari N, Blackaby WP, Patacchini R, Carzaniga L.
    Bioorg Med Chem Lett; 2021 Jun 01; 41():127975. PubMed ID: 33753262
    [Abstract] [Full Text] [Related]

  • 9. Molecular hybridization yields triazole bronchodilators for the treatment of COPD.
    Jones LH, Burrows J, Feeder N, Glossop P, James K, Jones RM, Kenyon AS, Patel S, Roberts DF, Selby MD, Strang RS, Stuart EF, Trevethick MA, Watson J, Wright KN, Clarke N.
    Bioorg Med Chem Lett; 2015 Nov 15; 25(22):5121-6. PubMed ID: 26471092
    [Abstract] [Full Text] [Related]

  • 10. [Tiotropium bromide for treating chronic obstructive pulmonary disease].
    Uteshev DB, Buniatian ND, Kovaleva VL.
    Eksp Klin Farmakol; 2010 Nov 15; 73(11):15-8. PubMed ID: 21254592
    [Abstract] [Full Text] [Related]

  • 11. Choice of bronchodilator therapy for patients with COPD.
    Wedzicha JA.
    N Engl J Med; 2011 Mar 24; 364(12):1167-8. PubMed ID: 21428773
    [No Abstract] [Full Text] [Related]

  • 12. [Regulation of bronchial tone in chronic obstructive pulmonary disease (COPD): role of muscarinic receptors].
    Abad Santos F, Novalbos J, Gallego Sandín S, Gálvez Múgica MA.
    An Med Interna; 2003 Apr 24; 20(4):201-5. PubMed ID: 12768836
    [Abstract] [Full Text] [Related]

  • 13. Tiotropium sustains the anti-inflammatory action of olodaterol via the cyclic AMP pathway.
    Costa L, Roth M, Miglino N, Keglowich L, Zhong J, Lardinois D, Tamm M, Borger P.
    Pulm Pharmacol Ther; 2014 Feb 24; 27(1):29-37. PubMed ID: 24269928
    [Abstract] [Full Text] [Related]

  • 14. Tiotropium increases PPARγ and decreases CREB in cells isolated from induced sputum of COPD patients.
    Holownia A, Mroz RM, Skopinski T, Kolodziejczyk A, Chyczewska E, Braszko JJ.
    Adv Exp Med Biol; 2013 Feb 24; 756():9-14. PubMed ID: 22836613
    [Abstract] [Full Text] [Related]

  • 15. NVA237, a long-acting muscarinic antagonist, as an emerging therapy for chronic obstructive pulmonary disease.
    Vogelmeier C, Banerji D.
    Ther Adv Respir Dis; 2011 Jun 24; 5(3):163-73. PubMed ID: 21511677
    [Abstract] [Full Text] [Related]

  • 16. [Other forms of bronchodilation].
    Izquierdo Alonso JL, Malo de Molina R.
    Arch Bronconeumol; 2004 Mar 24; 40 Suppl 1():23-9. PubMed ID: 16137446
    [No Abstract] [Full Text] [Related]

  • 17. Glycopyrrolate/formoterol (Bevespi Aerosphere) for COPD.
    Med Lett Drugs Ther; 2016 Oct 10; 58(1505):130-132. PubMed ID: 27701364
    [No Abstract] [Full Text] [Related]

  • 18. The scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in COPD.
    Cazzola M, Molimard M.
    Pulm Pharmacol Ther; 2010 Aug 10; 23(4):257-67. PubMed ID: 20381630
    [Abstract] [Full Text] [Related]

  • 19. Future of chronic obstructive pulmonary disease management.
    D'Urzo A, Vogelmeier C.
    Expert Rev Respir Med; 2012 Jun 10; 6(3):285-99. PubMed ID: 22788943
    [Abstract] [Full Text] [Related]

  • 20. The potential for aclidinium bromide, a new anticholinergic, in the management of chronic obstructive pulmonary disease.
    Maltais F, Milot J.
    Ther Adv Respir Dis; 2012 Dec 10; 6(6):345-61. PubMed ID: 23075544
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.